Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol
Rhea-AI Summary
ADIA Nutrition (OTCQB: ADIA) filed a provisional patent application with the United States Patent and Trademark Office on November 12, 2025 for a novel medical protocol aimed at enhancing regenerative outcomes.
The patent pending protocol reportedly uses unique procedural and biological mechanisms and gives ADIA a 12-month window to advance research, partnerships, and commercialization while preserving strategic confidentiality.
The company invited clinic owners and healthcare practitioners to inquire about licensing and integration of its regenerative therapies and said further updates will follow as development progresses.
Positive
- Provisional patent filed with USPTO on November 12, 2025
- Patent pending grants 12 months to advance research and partnerships
- Company positions itself as a leader in regenerative medicine IP
Negative
- Provisional filing is not an issued patent and may not be granted
- No clinical trial results or quantitative efficacy data disclosed
News Market Reaction
On the day this news was published, ADIA gained 15.79%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - November 12, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes.
This Patent Pending innovation represents a significant advancement in ADIA's mission to deliver cutting-edge, science-backed therapies. The proprietary protocol leverages unique procedural and biological mechanisms previously unexplored in clinical practice, positioning the company at the forefront of regenerative medicine.
"Securing this provisional patent marks a pivotal step in protecting our intellectual property while accelerating development of next-generation health solutions," Larry Powalisz, CEO of Adia Nutrition. "This filing underscores ADIA's commitment to innovation that delivers real clinical value."
The Patent Pending status allows ADIA to advance research, partnerships, and commercialization pathways over the next 12 months while maintaining strategic confidentiality.
ADIA Nutrition plans to provide further updates as development progresses.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273994
FAQ
What did ADIA (OTCQB: ADIA) announce on November 12, 2025?
What does the ADIA provisional patent mean for investors and partners?
Does ADIA's provisional patent guarantee a granted patent for the protocol?
Can clinic owners license ADIA's regenerative therapies now?
Who should investors contact for more information about ADIA's patent filing?
Will ADIA provide clinical data or updates about the protocol timeline?
